Open Access
Subscription or Fee Access
Importance of Immunological Aspects in the Treatment and Vaccine Development of COVID-19
Abstract
COVID-19, a coronavirus disease spread by SARS-COV-2 virus is a highly contagious disease which leads to severe acute respiratory syndrome. It has highly jeopardized the whole globe in a pandemic situation. This disease originated from Wuhan, China in December 2019. The outbreak of this virally spread disease was very rapid and it also appeared to be life threatening. This article lays out a brief overview about the virus, its mechanism, role of immune organs and the targets by which virus can be irradicated. The article also acknowledges the current treatments available for the prevention of the disease, along with the role of herd immunity and the strategies for vaccine development in addition with the available vaccines against COVID-19 and the post COVID complications. Altogether, this article will assist in improving the understanding of the current scenario and the available vaccines against the virus. Till date, there is no specific therapy available to prevent or treat COVID-19 rather than vaccines, indeed potential medicinal moiety that may block the virus progression at various steps during infection along with helping to strengthen the antiviral immune defence of the host, reducing the situation of cytokine storm, control the oxidative stress due to comorbidity and prevent the chances of recurrence is urgent need of today’s time.
Keywords
References
Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8.
Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta - Mol Basis Dis. 2020;1866(10):165878.
Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(August):237–61.
Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):407–12.
Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020;178(March):104792
Romano M, Ruggiero A, Squeglia F, et al. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells. 2020;9(5):1–22.
Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275–301.
Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471–82.
Ludwig S, Zarbock A. Coronaviruses and SARS-CoV-2: A Brief Overview. Anesth Analg. 2020;131(1):93–6.
Goldsmith CS, Tatti KM, Ksiazek TG, et al. Ultrastructural Characterization of SARS Coronavirus. Emerg Infect Dis. 2004;10(2):320–6.
Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity [Internet]. 2020;53(2):248–63.
Yi Y, Lagniton PNP, Ye S, et al. COVID-19: What has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–66.
Akkoc T. Immune Responses to SARS-CoV,MERS-CoV and SARS-CoV-2, 2020;(June):5–12.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J Allergy Immunol. 2020;38(1):1–9.
Shin H, Kim Y, Kim G, et al. Immune responses to MERS coronavirus during the acute and convalescent phases of human infection. (July 2018):1–30.
Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010;125(2 SUPPL. 2):S24–32.
Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619–29.
Lim Y, Ng Y, Tam J, et al. Human Coronaviruses: A Review of Virus–Host Interactions. Diseases. 2016;4(4):26.
Conti P, Ronconi G, Caraffa A, et al. induction ofpro-inflammatory cytokines (il-1 and il-6) and lung inflammation bycoronavirus-19 (covi-19 or sars-cov-2): anti-inflammatory strategies (2020). 2020;34(2).
García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020;11(June):4–8.
Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–73.
Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020;256(June):117900.
Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32.
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Vol. 75, Allergy: European Journal of Allergy and Clinical Immunology. 2020. 1564–1581 p.
Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11.
Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):1–16.
Hosseiny M, Kooraki S, Gholamrezanezhad A, et al. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. American Journal of Roentgenology. 2020 May;214(5):1078-82. 2020;(October):1–5.
Frediansyah A, Nainu F, Dhama K, et al. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Heal. 2020;(July)
Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494):1–7.
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. N Engl J Med. 2020;382(24):2327–36.
Bonam SR, Muller S, Bayry J, et al. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy. 2020;0(0).
Tripathy S, Dassarma B, Roy S, et al. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
Yousefi B, Valizadeh S, Ghaffari H, et al. A global treatment for coronaviruses including COVID-19. J Cell Physiol. 2020;235(12):9133–42.
Uzunova K, Filipova E, Pavlova V, et al. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020;131(August):110668.
Osborne V, Davies M, Lane S, et al. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf. 2020;43(8):809–21.
Khalili JS, Zhu H, Mak NSA, et al. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–6.
Tam RC, Lau JYN, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother. 2001;12(5):261–72.
Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J Infect Public Health. 2020;13(9):1187–95.
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370–6.
Raabe VN, Kann G, Ribner BS, et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever. Clin Infect Dis. 2017;65(5):855–9.
Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92(9):1475–83.
Sumel Ashique, ‘Virafin’ A new hope to treat nCOVID-19?- An editorial letter. International journal of research publication and reviews .2021, vol 2 issue 4, 601-602.
Leon Caly, Julian D. Druce, Mike G. Catton, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020 volume-178, 1-16.
Dhyuti Gupta, Ajaya Kumar Sahoo, Alok Singh. Ivermectin: potential candidate for the treatment of COVID-19. Brazilian journal of infectious diseases. July-august-2020,1-2.
Heidary, F., Gharebaghi, R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 73, 2020 593–602.
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA - J Am Med Assoc. 2020;323(16):1582–9.
Xi Y. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Signal Transduct Target Ther. 2020;5(1):7–10.
Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52(SUPPL. 1).
Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–46.
Rizk JG, Kalantar K, Mehra MR, et al. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;(0123456789).
Chen K, Wang S, Wang S, et al. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. 2019;817–21.
Felsenstein S, Herbert JA, Mcnamara PS, et al. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215(April):108448.
Smith DA, Germolec DR. Introduction to Immunology and Autoimmunity Diseases. 1999;107(October):661–5.
Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012 Jan;22(1):2-17. doi: 10.1002/rmv.706. Epub 2011 Sep 8. PMID: 21905149; PMCID: PMC3256278.
Brandon J. Webb MD, Whitney Buckel, Todd Vento, et.al. Real world effectiveness and tolerability of monoclonal antibodies for ambulatory patients with early COVID-19. medRxiv 2021.03.15.doi: 21253646
Taylor, P.C., Adams, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 21, 382–393 (2021).
Weinreich DM, Sivapalasingam S, Norton T, et al. Trial Investigators. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17. PMID: 33332778; PMCID: PMC7781102.
Tillu G, Chaturvedi S, Chopra A, et al. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis. J Altern Complement Med. 2020;26(5):360–4
Gautam S, Gautam A, Chhetri S, et al. Immunity against COVID-19: Potential role of Ayush Kwath. J Ayurveda Integr Med. 2020;(xxxx).
Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15(8):646–55.
Aricò E, Bracci L, Castiello L, et al. Are we fully exploiting type I Interferons in today’s fight against COVID-19 pandemic? Cytokine Growth Factor Rev. 2020;54:43–50
Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;2.
Frederiksen LSF, Zhang Y, Foged C, et al. The Long Road toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Front Immunol. 2020;11(July):1–26.
Yager EJ. Antibody-dependent enhancement and COVID-19: Moving toward acquittal. Clin Immunol. 2020;217:108496. doi:10.1016/j.clim.2020.108496
Lee, W.S., Wheatley, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 5, 1185–1191 (2020). https://doi.org/10.1038/s41564-020-00789-5
RATHER, R. A., ISLAM, T., et al. (2021). Development of vaccine against coronavirus disease 2019 (COVID-19) in india. Asian Journal of Advances in Medical Science, 3(2), 13-21.
Gajanan N Sapkal, PhD, Pragya D Yadav, PhD, Raches Ella, MS, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2, Journal of Travel Medicine, Volume 28, Issue 4, May 2021, taab051, https://doi.org/10.1093/jtm/taab051
Kalra G, Mathur VP. Vaccine Literacy. J South Asian Assoc Pediatr Dent 2021; 4 (1):1-2.
https://www.cdc.gov/
https://www.nytimes.com/ , National Centre for Biotechnology Information.
Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021 Feb 20;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4. Epub 2021 Feb 2. PMID: 33545098; PMCID: PMC7906719.
https://en.m.wikipedia.org/wiki/Sputnik_V_COVID-19_vaccine,
Ghiasi N, Valizadeh R, Arabsorkhi M, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa.2021;7(2):e31.DOI:10.34172/ipp.2021.31.
Shahcheraghi SH, Ayatollahi J, Aljabali AA, et al. An overview of vaccine development for COVID-19. Ther Deliv. 2021 Mar;12(3):235-244. doi: 10.4155/tde-2020-0129. Epub 2021 Feb 24. PMID: 33624533; PMCID: PMC7923686.
Noor R. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Curr Clin Microbiol Rep. 2021 Mar 3:1-8. doi: 10.1007/s40588-021-00162-y. Epub ahead of print. PMID: 33686365; PMCID: PMC7927780
Tregoning, J.S., Flight, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol (2021). https://doi.org/10.1038/s41577-021-00592-1.
Takahashi S, Metcalf CJE, Ferrari MJ, et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science (80-). 2015;347(6227):1240–2.
Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985;318(6044):323–9.
Britton T, Ball F TP. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. J Phys A Math Theor. 2011;44(8):1–9. Available from:
Delamater PL, Street EJ, Leslie TF, et al. Complexity of the basic reproduction number (R0). Emerg Infect Dis. 2019;25(1):1–4.
Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737–41.
Xia Y, Zhong L, Tan J, et al. How to Understand “Herd Immunity” in COVID-19 Pandemic. Front Cell Dev Biol. 2020;8(September):1–7.
Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583–4.
Silva Andrade B, Siqueira S, de Assis Soares WR, et al. Long-Covid and Post-Covid Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021; 13(4):700.
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: A Journal of Immunology